1xbet 리뷰., Ltd.

1xbet 리뷰., Ltd. (Otsuka) announces that Novartis Pharma K.K. (Novartis Pharma) has launched1xbet 리뷰_® 1xbet 리뷰 12.5 mg / 31.25 mg (generic name: sacubitril valsartan sodium hydrate, hereinafter referred to as "1xbet 리뷰Granular Tablets"), an angiotensin receptor neprilysin inhibitor (ARNI) and 1xbet 리뷰 with chronic heart failure.

In Japan, activities to provide in1xbet 리뷰mation on1xbet 리뷰to healthcare professionals will be conducted by Novartis Pharma and 1xbet 리뷰 based on a co-promotion agreement.

About 1xbet 리뷰

1xbet 리뷰is classified as an angiotensin receptor neprilysin inhibitor (ARNI) with a mechanism of action that simultaneously inhibits neprilysin (NEP) and the renin-angiotensin-aldosterone system (RAAS).

In Japan,1xbet 리뷰Tablets was approved 1xbet 리뷰 the indication of chronic heart failure and hypertension in June 2020 and September 2021, respectively. The indication, dosage and administration of1xbet 리뷰Tablets 1xbet 리뷰 the treatment of chronic heart failure in pediatric patients were approved in February 2024.

Pediatric chronic heart failure is often caused by congenital heart disease and cardiomyopathy. Patients may not only experience symptoms such as difficulty breathing, but also develop aggravated cardiac hypertrophy and cardiomegaly with the disease progression, which may result in arrhythmia and sudden death. There1xbet 리뷰e, early diagnosis and appropriate treatment are essential.^1,2,3

Reference

1. Mitsunori Nishiyama, "Diagnosis and Initial Treatment of 1xbet 리뷰 Heart Failure," 1xbet 리뷰 Clinical Practice 2012; 65(7):1621-6.
2. Sharma M, Nair M, Jatana SK, et al. "Congestive Heart Failure in Infants and Children." Med J Armed 1xbet 리뷰ces India; 59(3): 2003, 228-33.
3. Andrews RE, Fenton MJ, Ridout DA, et al. "New-onset heart failure due to heart muscle disease in childhood: a prospective study in the United Kingdom and Ireland." Circulation; 2008, 117(1):79-84.